Exciting news from our portfolio company, Vivtex – they recently entered into a partnership agreement worth up to $2.1B to develop oral biologics for obesity, diabetes, and cardiometabolic disease.

Novo Nordisk is one of the leaders in cardiometabolic disease, and we love seeing pharma partner with early-stage innovators like Vivtex. We recently partnered with Novo Nordisk via our Portal Pathbreakers program to help them find emerging startups focused in the cardiometabolic space. Our relationship with large-scale pharmaceutical organizations is one of the key differentiators as to why companies choose Portal.